Role of an Ayurvedic formulation 'Kalyanaka Ghrita' in mild cognitive impairment: A single-patient, quasi-randomized, controlled, open-label N-of-1 trial.
Swati Sharma, Arun Kaushik, Sankha Shubhra Chakrabarti et al.
✦ AI-curated · Sources linked
From the abstract
To assess the efficacy and safety of Kalyanaka Ghrita in a patient diagnosed with Mild Cognitive Impairment (MCI) using an N-of-1 trial design.
Reported results
KG administration improved overall cognitive abilities, as indicated by global HMSE scores (posterior probability >97%, 95% HPDI excluding zero), with the most substantial gains in orientation (posterior probability >98%) and recall (posterior probability >93%) domains. Reduction in CDR-Sum of Boxes scores indicated strong improvement (posterior probability >98%; 95% HPDI excluded zero).
Authors' conclusions
KG produced measurable improvements across cognitive, functional, and affective domains in a patient with MCI, suggesting a potential role in the management of early cognitive decline. The formulation was well tolerated. The study also demonstrates the feasibility of applying an N-of-1 trial within Ayurveda.